10-Q: Dominari Holdings Reports Significant Revenue Growth but Losses Widen in Q1 2025
Quarterly Report
Dominari Holdings Inc. reports a substantial increase in revenue for Q1 2025, driven by its financial services segment, but experiences a significant widening of net losses due to increased operating expenses and stock-based compensation.
Summary
- Dominari Holdings Inc. reported revenues of $8.112 million for the three months ended March 31, 2025, compared to $1.367 million for the same period in 2024.
- The company experienced a net loss of $32.488 million, or $3.02 per share, for Q1 2025, compared to a net loss of $5.441 million, or $0.91 per share, for Q1 2024.
- The increase in net loss was primarily due to a significant rise in general and administrative expenses, including stock-based compensation.
- As of March 31, 2025, the company had cash and cash equivalents of $6.315 million and marketable securities of $12.555 million.
- The company's working capital amounted to approximately $28.5 million as of March 31, 2025.
- Dominari operates in two reportable segments: Dominari Financial and Legacy AIkido.
- Dominari Securities had net capital of approximately $9.39 million as of March 31, 2025, exceeding the net capital requirement of $0.41 million by approximately $8.98 million.
- The company issued 3,876,054 shares of common stock during the quarter.
Sentiment
Score: 4
Explanation: The document presents mixed signals. While revenue growth is positive, the significant widening of net losses and the identified material weakness in internal controls raise concerns. The company's transition strategy and potential need for additional capital also contribute to a cautious sentiment.
Positives
- Significant revenue growth driven by the financial services segment.
- Dominari Securities exceeds net capital requirements.
- Collection of $1.1 million on notes receivable.
- Sale of long term investments of $0.5 million.
- Collection of principal from employee loans of $0.1 million.
Negatives
- Substantial widening of net losses due to increased operating expenses and stock-based compensation.
- Material weakness in internal controls over financial reporting.
- Realized loss of approximately $1 million on marketable securities.
- The company recognized $0.2 million realized and unrealized gain over the three months ended March 31, 2025, versus $0.9 million loss during the three months ended March 31, 2024 on notes receivable.
Risks
- The company's ability to generate sufficient cash flow to meet its obligations is dependent on its ability to execute its longer-term business plan.
- The company may need to raise additional capital sooner than expected.
- Volatility and weakness in the public markets could make it more difficult to raise additional capital.
- The company is subject to legal proceedings, including a claim against Dominari Securities related to the hiring of registered representatives.
- Material weakness in internal controls over financial reporting could lead to material misstatements in the company's financial statements.
Future Outlook
The company intends to finance its activities through managing current cash and cash equivalents, seeking additional funds through the sale of additional securities, and seeking additional liquidity through credit facilities or other debt arrangements.
Industry Context
The company is transitioning from a biotechnology company to a financial services company, which involves acquisitions and partnerships in the wealth management, investment banking, sales and trading, asset management, and insurance sectors.
Comparison to Industry Standards
- The document does not contain sufficient information to make a detailed comparison to industry standards.
- However, the company's transition into financial services and its focus on acquisitions and partnerships are common strategies in the industry.
- The company's net capital position at Dominari Securities appears to be healthy, exceeding regulatory requirements.
Legal Proceedings
- In March 2024, the Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives former employer.
- This notice was filed against the Company's subsidiary Dominari Securities.
- The Company does not agree with the claim of the plaintiff and will defend itself accordingly.
Related Party Transactions
- From time to time, Company participates in offerings of securities as an underwriter in transactions in which Revere is also participating as an underwriter.
- On such transactions, the Company earned $368,000 and $20,000 in the three months ending March 31, 2025 and 2024, respectively.
- Certain of the Company's investments are made through related party special purpose vehicles.
- The Company earns revenues for managing certain pooled investment vehicles which are related parties.
- In addition to managing these related party pooled investment vehicles, the Company also acts as placement agent and earns placement fees, of which $2.8 million is included in underwriting revenues.
- On February 4, 2025 the Company deposited $2.5 million from brokerage accounts on behalf of SPV Series XII for the purchase of 1,752. shares of xAI common stock.
Stakeholder Impact
- Shareholders may be concerned about the widening net losses and the material weakness in internal controls.
- Employees may be affected by changes in staffing and resource allocation.
- Customers may be impacted by the company's transition and changes in service offerings.
- Suppliers and creditors may be affected by the company's financial performance and ability to meet its obligations.
Next Steps
- The company is actively increasing the quantity and quality of our internal accounting personnel and has engaged external valuation specialists and accounting advisors with financial reporting expertise, so as to provide the Company with resources sufficient to properly design and implement internal controls which will prevent and detect material misstatements to the financial statements in a timely manner.
- The company will continue to implement its business strategy, manage cash flow, and seek additional funding as needed.
Key Dates
| Date | Description |
|---|---|
| 1967 | Company founded as Spherix Incorporated. |
| 2017 | Company operated as a biotechnology company. |
| 2022-06 | Company formed Dominari Financial Inc. |
| 2022-09-09 | Dominari Financial entered into the FPS Purchase Agreement. |
| 2022-10-04 | Initial Closing of the FPS Purchase Agreement. |
| 2023-03-20 | FINRA approved the Rule 1017 Application. |
| 2023-03-27 | Second closing of the FPS Purchase Agreement; FPS renamed Dominari Securities LLC. |
| 2023-10-13 | Company entered into Limited Liability Agreements with Dominari Manager LLC and Dominari IM LLC. |
| 2024-03 | Manager established various series of funds of the Master SPV. |
| 2024-03 | Company received a notice of petition of a filed action seeking relief related to the hiring in March 2024 of new registered representatives from the representatives former employer. |
| 2024-05-21 | Dominari Financial and Heritage Strategies LLC entered into the JV Agreement of Dominari Financial Heritage Strategies LLC. |
| 2025-02-10 | Company entered into securities purchase agreements for the sale of common stock and warrants. |
| 2025-02-11 | Board of directors approved a special cash dividend of $0.32 per share. |
| 2025-02-18 | 2,550,000 shares of common stock were issued related to advisory agreements. |
| 2025-03-03 | Special cash dividend of $0.32 per share was payable. |
| 2025-03-24 | American Innovative Robotics note was fully paid off. |
| 2025-03-31 | ADC completed a series of transactions providing for the launch of American Bitcoin Corp. |
| 2025-05-12 | Date of the report. |
Keywords
financial services, broker-dealer, investment banking, wealth management, fintech, Dominari Holdings, revenue, net loss, stock-based compensation, internal controls
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.